Lv11
10 积分 2024-07-05 加入
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
1小时前
待确认
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population
2小时前
已完结
The antibody–drug conjugate landscape
2个月前
已完结
Antibody–drug conjugates come of age in oncology
2个月前
已完结
Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
3个月前
已完结
Third-line Treatment for Metastatic Triple-negative Breast Cancer
3个月前
已完结
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan
3个月前
已完结
The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review
4个月前
已完结
Chimeric antigen receptor T cell therapy for autoimmune disease
5个月前
已完结
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
5个月前
已完结
皖公网安备34019202002308
